AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells

Shikonin induces necroptosis by reactive oxygen species activation in nasopharyngeal carcinoma cell line CNE-2Z

(2017) Zixuan Zhang et al.   JOURNAL OF BIOENERGETICS AND BIOMEMBRANES

Iron Oxide Nanoparticles Synergize with Erlotinib to Suppress Refractory Non-Small Cell Lung Cancer Cell Proliferation Through the Inhibition of ErbB/PI3K/AKT and PTEN Activation

(2017) Meili Zhang et al.   Journal of Biomedical Nanotechnology

Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma

(2017) Venugopal Vinod Prabhu et al.   JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY

Successful AZD9291 Therapy in Advanced Non–Small Cell Lung Cancer after Failure of HM61713

(2017) Chien-Wei Chen et al.   Journal of Thoracic Oncology

Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells

(2017) Zheng-Hai Tang et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

(2016) Daniel J Klionsky et al.   Autophagy

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

(2016) P. Ballard et al.   CLINICAL CANCER RESEARCH

Osimertinib: First Global Approval

(2016) Sarah L. Greig   DRUGS

Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

(2016) Don S. Dizon et al.   JOURNAL OF CLINICAL ONCOLOGY

Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells

(2016) Zhirui Zhang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

(2016) Shuhang Wang et al.   Journal of Hematology & Oncology

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLC

(2016) Melissa Bersanelli et al.   Journal of Thoracic Oncology

Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer

(2016) Kenzo Soejima et al.   Expert Review of Clinical Pharmacology

Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience

(2016) Ivana Sullivan et al.   Therapeutic Advances in Respiratory Disease

EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells

(2015) Shohei Sugita et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Mechanisms underlying 3-bromopyruvate-induced cell death in colon cancer

(2015) Yiming Sun et al.   JOURNAL OF BIOENERGETICS AND BIOMEMBRANES

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Autophagy contributes to gefitinib-induced glioma cell growth inhibition

(2014) Cheng-Yi Chang et al.   EXPERIMENTAL CELL RESEARCH

The PI3k inhibitors: new hopes in the battle against advanced NSCLC

(2014) Paola Sacco   Frontiers in Bioscience-Landmark

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup

(2014) Lei Wang et al.   PLoS One

Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M

(2014) Kwang Sup So et al.   PLoS One

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials

(2014) Barbara Melosky   Frontiers in Oncology

EGFR-Mediated Beclin 1 Phosphorylation in Autophagy Suppression, Tumor Progression, and Tumor Chemoresistance

(2013) Yongjie Wei et al.   CELL

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

(2013) Kadoaki Ohashi et al.   JOURNAL OF CLINICAL ONCOLOGY

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

(2013) Richard A. Ward et al.   JOURNAL OF MEDICINAL CHEMISTRY

Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer

(2013) Yuan-yuan Li et al.   LUNG CANCER

Induction of Autophagy Is an Early Response to Gefitinib and a Potential Therapeutic Target in Breast Cancer

(2013) Wieslawa H. Dragowska et al.   PLoS One

EGFR Tyrosine Kinase Inhibitors Activate Autophagy as a Cytoprotective Response in Human Lung Cancer Cells

(2011) Weidong Han et al.   PLoS One

The PI3-K/AKT-Pathway and Radiation Resistance Mechanisms in Non-small Cell Lung Cancer

(2009) Olga C.J. Schuurbiers et al.   Journal of Thoracic Oncology